Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 15/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093704 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31093707 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31093706 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL24495524 | 0.81 | LMNA (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL20324247 | 0.81 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL29686827 | 0.81 | LMNA (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31014478 | 0.81 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31015503 | 0.81 | CYP4F2 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL27227973 | 0.79 | CYP4F2 (0.45) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL23272983 | 0.79 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512087-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| EP-3560926-B1 | 6-AMINO-7,9-DIHYDRO-8H-PURIN-8-ONE COMPOUNDS AS BRK INHIBITORS | ONO PHARMACEUTICAL CO (JP) | 2022-02-23 | — | — | EP | disclosed |
| US-11052091-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| US-11052091-B2 | BRK inhibitory compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-06 | — | — | US | disclosed |
| EP-3560926-A1 | Brk INHIBITORY COMPOUND | Ono Pharmaceutical Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| WO-2018117177-A1 | Brk INHIBITOR COMPOUND | 小野薬品工業株式会社 | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315756-A1 | BRK INHIBITORY COMPOUND | BRI3BP, BLK, BRSK2 | CYP4F2 2604/4885CYP4A11 1171/4885ALDH1A1 3125/4885 |
| US-11512087-B2 | BRK inhibitory compound | BRI3BP, BLK, BRSK2 | CYP4F2 2604/4885CYP4A11 1171/4885ALDH1A1 3125/4885 |
| US-11052091-B2 | BRK inhibitory compound | BRI3BP, BRSK2, SBK3 | CYP4F2 1514/4885CYP4A11 750/4885ALDH1A1 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.